Background Direct-acting antivirals (DAAs) combination therapies from various mechanisms of action and families have been revolutionized the management landscape of chronic hepatitis C virus (HCV). Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) is approved to treat HCV genotype 4 (GT4) infection. Here, our objective was to delineate the efficacy and safety of OBV/PTV/r plus RBV in treating of Egyptian naïve patients infected with HCV GT4.

Methods a cohort of 100 Egyptian patients infected with HCV GT4 was allocated and administered orally OBV/PTV/r with RBV. The primary endpoint of our study was a sustained virological response (HCV RNA < 12 IU/mL) 12 weeks after the c

Background: Hepatitis C virus (HCV) infection is one of the most common infections associated with chronic kidney disease (CKD) patients undergoing hemodialysis (HD) in Iraq.

Aim of the study: To determine the prognostic factor value of Programmed Cell Death-1 (PD-1) and Programmed Cell Death Ligand-1 (PD-L1) immune checkpoint biomarkers among CKD patients with HCV infection under HD.

Methodology: ELISA technique was used for the measurement of the above-mentioned biomarkers in the serum of 90 Iraqi patients. The participants were divided into three groups; Group I included 30 patients infected with HCV without antiviral treatment, group II included 30 patients infected wit

Background: ;Hepatitis C virus (HCV) is a major cause of chronic liver disease. Approximately 85% of patients acutely infected with HCV progress to chronic liver disease with persistence of HCV-RNA for more than 6 months Among patients with chronic HCV infection , 15-20% progress to end-stage liver disease main transmission methods of the virus is by : blood and blood products ; sharing needles and acupuncture .Objective: To evaluate Iraqi patients infected with chronic HCV, including their treatment, and factors that affect their response to treatment .Methods :This study was performed at Gastroenterology and Hepatology hospital in Baghdad from January 2011 to March 2012.The study enrolled 90 patients with HCV Antibody positive (Ab +ve)

Background:
Hepatitis C Virus is the main causative agent of hepatitis among blood transfused patients, in which most chronic cases result in liver carcinoma.
Materials & Methods:
Enzyme-Linked Immunosorbent Assay for HCV, FNF- and IL-12p40 estimation with Recombinant Immunoblotting Assay (RIBA) as a confirmatory test for HCV, have been
applied for HCV detection in 80 HCV patients' samples in comparison with 30 samples for apparently healthy control, while viral load has been estimated using Branched-DNA (b-
DNA) technique for 32 randomly selected positive cases for HCV. Liver function test has been applied for patients' sera in comparison with control.
Results & Conclusions:
This study re

Objective(s): To measure serum C-reactive protein (CRP) titer as a predictive diagnosis of acute hepatitis C virus (HCV)
infection.
Methodology: Two hundred and ten patients with acute HCV infection and 234 apparently healthy individuals as
control group were enrolled in this study in Baghdad medical city (Teaching Laboratories). The patents include
74(35.2%) females and 136 (64.8%) males with mean age (27±16.5) years. The control group includes 114 (48.7%)
females and 120 (51.3%) males with mean age (26±5.8) years. Blood samples were collected from out patients from
Alfadul in Baghdad city. Sera were separated and stored at 20 0
C. The diagnosis of acute HCV infection was based on
detection of HC Ag and anti- H

Background: Autoantibodies are frequently found in patients with chronic hepatitis C, which suggests that HCV elicit an immune response in the host. ). The relationship of type-2 AIH to
chronic hepatitis C (HCV) is an interesting and as yet unresolved problem. Importantly, antibodies to liver/kidney microsome type-1 (LKM1), the serologic marker of type 2-AIH, have been recognized in serum of some patients with chronic hepatitis C.
Methods: Anti-liver kidney microsome type 1 (LKM-1) autoantibodies were studied by indirect immuno florescence assay (IIF) and confirmed by immunoblot in the serum of 73 Iraqi patients with autoimmune hepatitis (AIH) in comparison with 50 patients control (HCV infection) and 50&nb

Background: Chronic hepatitis B virus (HBV) infection is a common health problem that has a worldwide distribution. Apart from the direct effect of the virus on the liver, there are many extrahepatic manifestations among which the probable effect on bone turnover associated with low bone mineral density (BMD). Objectives: This study aimed to determine the association between treated and untreated chronic HBV infection with BMD. Methods: This is a cross-sectional study which included a total of 48 patients with chronic HBV (28 patients treated with tenofovir-disoproxil-fumarate [TDF] antiviral drug and 20 patients have not yet started treatment). Other age- and sex-matched 30 apparently healthy individuals were recruited to represent the hea

Epstein-Barr Virus (EBV) infection is associated with broad spectrum of clinical manifestationsdepending on the immune status of the host, To analyze their possible role in the complication ofautoimmune hepatitis, we investigated (30) female patients with autoimmune hepatitis type-1 of(10-40)years and 25 healthy female of same ages(control groups). Both groups were carried outto measure the levels of EBV-CA IgM, IgG Ab, EBV-EA IgM, IgG Ab, and EBV-NA IgM, IgGAb using indirect immunoflourescent assay (IFAT).The prevalence of EBV-CA IgM, IgG Ab were(10%,20%) and EBV-EA IgM, IgG Ab were (10% and20%) respectively, while the prevalence ofEBV-NA IgG Ab was( 3.33%) and there are no prevalence of EBV-NA IgM Ab. There weresignificant differences (P

To determine the seroprevalence of hepatitis B markers in chronic hepatitis B patients, 75 patients with chronic hepatitis B virus of ages (8-70) years have been investigated and compared with 50 apparently healthy individuals. All the studied groups were carried out to measure (HBsAg), (HBsAb), (HBeAg), (HBeAb), and (Total HBcAb) by Enzyme linked immunosorbent assay (ELISA) technique. The percentage distribution of HBsAg was (86.67%) and HBsAb was (1.33%) in sera of CHB patients and there were a highly significant differences (P<0.01) when compared between studied groups, while, the percentage distribution of HBeAg was (22.67%) in sera of CHB patients and the significant represent the difference in distribution of HBeAg as infection but no